Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2023 / Dec / Oncology Chronicles
Oncology Oncology Technology and innovation

Oncology Chronicles

We take a trip down memory lane to view our favorite oncology articles

By Georgia Hulme 12/05/2023 Review 3 min read

Share

Here at The Pathologist, we have covered almost ten years worth of cancer content. From technological innovations to scientific breakthroughs, we have seen rapid progress in cancer detection and diagnosis across the globe. So, join us today as we delve into the world of oncology – rediscovering some of our most interesting articles, news stories, and interviews with experts from the field.

In this article, we discuss hairy cell leukemia – a rare cancer that makes up about one in every 50 leukemia cases. We spoke to Graeme Quest from the Hairy Cell Leukemia Foundation to find out more about the experiences of professionals treating patients with HCL.

“It’s still a bit of a mystery where hairy cells come from – they are memory B cells, but don’t seem to pass through germinal centers or gain CD27 like most memory B cells. We know that the BRAF V600E mutation is found in the early hematopoietic stem cells in HCL and some histiocytic neoplasms, though the two virtually never coexist or occur sequentially – so there is some added mystery in what commits these stem cells to their path.”

Read the article here

Researchers from Nagoya University, Japan, have turned to ovarian cancer extracellular vesicles (EVs) – including exosomes – as promising biomarkers.

“Originally, the challenge was to find ovarian cancer-specific proteins in ovarian cancer EVs. We tested multiple methods, including unique ELISA for EV detection, western blotting or referring database for discovering targets and validating them,” says Yokoi.

Read the article here

Adil Menon discusses the current state of antiangiogenic therapy and the potential of vascular normalization.

“The potential benefits of vascular normalization as a treatment strategy have been experimentally demonstrated. Tumor vasculature is more complex, dilated, tortuous, hyperpermeable, and disorganized than normal blood vessels. These complex, leaky vessels represent a limiting factor for the efficacy of combination therapy – but normalizing doses of an anti-VEGFR2 antibody helps reverse this phenotype in favor of a more homogeneous distribution of functional tumor vessels.”

Read the article here

We sit down with HRH Princess Dina Mired of Jordan, President of the Union for International Cancer Control, humanitarian, and health activist, to discuss cancer advocacy, her role at the Union for International Cancer Control, and much more!

“I am probably the first non-medical person to be at the helm of such an institution but, given my own experiences, I felt that I truly understood the patient’s perspective. I also come from the developing world, and I thought it was important for the UICC to have someone who had experienced the challenges and inadequacies faced by the places that they were aiming to help.”

Read the article here

Mark Kruzel talks about how closer pathology-oncology care team coordination is vital to fully benefit from the value of precision therapies and improve patient outcomes.

“One of the tools clinicians have at their disposal to inform a patient’s care is the companion diagnostic, which helps match a patient to a specific therapy, by identifying if a patient’s tumor has a specific gene change or biomarker that can be targeted by a certain treatment. Often, a companion diagnostic can supplement a biopsy.”

Read the article here

Dean Bitan emphasizes the role of deep learning and artificial intelligence to democratize genomic screening and transform patient care.

“Leveraging AI to reduce testing costs and make genomic screening available to everyone, everywhere, will make a real impact on the quality of patient care – not only by helping to select the most appropriate treatments, but also by speeding up the selection process to reduce wait times and anxiety for patients and families.”

Read the article here

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Georgia Hulme

Associate Editor for the Pathologist

More Articles by Georgia Hulme

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.